Imunon shares up over 150% as ovar­i­an can­cer treat­ment ex­tends sur­vival in Phase 2

Imunon shares sky­rock­et­ed Tues­day af­ter the biotech re­port­ed pos­i­tive sur­vival da­ta from a mid-stage tri­al of its IL-12 boost­ing im­munother­a­py on top of stan­dard of …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER